Your Source for Venture Capital and Private Equity Financings

Scorpion Therapeutics Launches with $108M

2020-10-26
BOSTON, MA, Scorpion Therapeutics announced the closing of a $108 million Series A financing, led by Atlas Venture, Omega Funds, and Vida Ventures.
Scorpion Therapeutics, a precision oncology company, announced the closing of a $108 million Series A financing, led by Atlas Venture, Omega Funds, and Vida Ventures, with participation from Abingworth and Partners HealthCare Innovation. The financing will be used to advance Precision Oncology 2.0., the next wave in precision medicine, with the goal of delivering small molecule drugs that are safe and well-tolerated and that can provide deeper, more durable responses to many more people with cancer.

Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion's experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading